|
Patent landscape, scope, and claims: |
United States Patent 5,866,590 (Tiagabine Stabilized with Ascorbic Acid or Vitamin E Derivatives): Claim Scope, Validity Anchors, and US Patent Landscape
United States Patent 5,866,590 claims tiagabine (or tiagabine salts) stabilized with antioxidants, specifically ascorbic acid, and alternatively a blend of alpha-tocopherol plus ascorbyl palmitate, formulated with a pharmaceutically acceptable carrier. The claims also cover a preparation process using mixture formation and melt granulation under low water vapor and low oxygen conditions. This creates a relatively narrow but execution-relevant IP fence around (i) antioxidant selection and ratio ranges, and (ii) manufacturing atmosphere/process conditions.
What patents protect tiagabine compositions stabilized with antioxidants like ascorbic acid and alpha-tocopherol/ascorbyl palmitate?
What is the core claim invention in US 5,866,590
The patent’s claim set is directed to two antioxidant systems for tiagabine compositions:
-
Ascorbic acid stabilization system
- Claim 1: tiagabine (or acceptable salt) + ascorbic acid (amount sufficient to stabilize) + carrier.
- Claim 3: ascorbic acid at 5–25 parts by weight per 100 parts tiagabine hydrochloride.
- Claims 4–6: process claims including melt granulation and “low water vapor pressure and low oxygen pressure.”
-
Mixed vitamin E derivative system
- Claim 7: tiagabine (or acceptable salt) + mixture of alpha-tocopherol and ascorbyl palmitate (amount sufficient to stabilize) + carrier.
- Claim 9: alpha-tocopherol + ascorbyl palmitate at 5–25 parts by weight per 100 parts tiagabine hydrochloride.
- Claims 10–12: analogous process claims including melt granulation under low water vapor and low oxygen pressure.
Practical scope impact: the claims are not framed as “any antioxidant.” They are built around specific antioxidant agents (ascorbic acid; or alpha-tocopherol plus ascorbyl palmitate), and they include numeric loading ranges tied to tiagabine hydrochloride, plus process conditions.
What is the scope of each claim in US 5,866,590 (composition vs process) and where are the infringement hotspots?
Claim-by-claim scope map
Claim 1: tiagabine + ascorbic acid + carrier
- Covered subject matter: any pharmaceutical composition containing tiagabine (or pharmaceutically acceptable salt) and ascorbic acid in a stabilizing amount, plus a pharmaceutically acceptable carrier.
- Infringement hotspot: proving the accused product contains ascorbic acid and that its amount is “sufficient to stabilize” tiagabine. This language can expand beyond the numeric range of claim 3, depending on interpretation and evidence of stabilization performance.
Claim 2: antioxidant in powder form
- Claim dependency effect: requires ascorbic acid (from claim 1) to be the antioxidant “in the form of a powder.”
- Hotspot: product must use a powdered antioxidant ingredient rather than, for example, solutions or alternative delivery forms.
Claim 3: ascorbic acid at 5–25 parts by weight per 100 parts tiagabine hydrochloride
- Hard numeric boundary: if a competitor uses less than 5% w/w or more than 25% w/w (scaled to tiagabine HCl), this claim may not read on the product.
- Hotspot: formulation disclosure and assay quantification. This is the easiest claim to test analytically.
Claim 4: process for making the composition
- Covered subject matter: forming a mixture of tiagabine (salt), ascorbic acid, and carrier.
- Hotspot: simply mixing in the claimed components can fall within “forming a mixture,” even before granulation, depending on how courts construe “mixture” and whether subsequent steps are required in the asserted process.
Claim 5: melt granulation
- Adds specificity: requires melt granulation of the mixture.
- Hotspot: melt granulation is not always used in standard solid dosage manufacturing; proof requires manufacturing records, batch reports, or credible process testimony.
Claim 6: low water vapor pressure and low oxygen pressure
- Adds atmosphere/process-condition limitation.
- Hotspot: “low water vapor pressure” and “low oxygen pressure” are operational parameters. Infringement turns on measurable chamber/environment metrics.
Claim 7: tiagabine + alpha-tocopherol + ascorbyl palmitate + carrier
- Covered subject matter: tiagabine with a stabilization system formed by a mixture of alpha-tocopherol and ascorbyl palmitate.
- Hotspot: accused formulation must contain both components together, not just one antioxidant.
Claim 8: antioxidant in powder form
- Dependency: requires the antioxidant system (as in claim 7) to be in powder form.
- Hotspot: again turns on ingredient physical form.
Claim 9: 5–25 parts by weight per 100 parts tiagabine hydrochloride
- Numeric boundary: same style of range limitation as claim 3, but now applied to the combined alpha-tocopherol and ascorbyl palmitate antioxidant content as used for stabilization.
Claim 10: process for making the composition
- Form mixture of tiagabine (salt), alpha-tocopherol and ascorbyl palmitate, and carrier.
- Hotspot: process scope includes basic mixing.
Claim 11: melt granulation
- Adds melt granulation requirement.
Claim 12: low water vapor pressure and low oxygen pressure
- Adds process-atmosphere limitation identical in character to claim 6.
Infringement theory options
- Product infringement: claims 1–3 (ascorbic acid) or 7–9 (alpha-tocopherol/ascorbyl palmitate) generally require that the final pharmaceutical composition contains the specified antioxidant(s) at stabilizing amounts, with the salt form/ratio limitations where applicable.
- Process infringement: claims 4–6 and 10–12 require evidence of manufacturing steps: mixture formation, melt granulation, and controlled low moisture/oxygen conditions.
Key implication for competitors: a workaround is not only antioxidant substitution. If they avoid melt granulation or operate in different moisture/oxygen regimes, process claims become harder to assert.
How many patents cover the same tiagabine stabilization space in the US, and where does 5,866,590 sit in the broader estate?
What the landscape typically includes for tiagabine solid oral formulations
While US 5,866,590 is explicitly antioxidant-stabilization focused, tiagabine formulation patents in practice tend to cluster into:
- Drug substance stabilization (oxidation-sensitive behavior addressed by antioxidants)
- Solid-state form stabilization (crystal form, polymorph control)
- Manufacturing process claims (granulation, drying, atmosphere control)
- Dosage form compositions (tablet/capsule excipients, binders, carriers)
- Salt form selection (tiagabine free base vs hydrochloride vs other salts)
Where 5,866,590 is positioned: it is a solid formulation stability patent with both composition and process claims that are tightly tethered to specific antioxidant chemistry and to melt granulation under controlled low water/oxygen.
When does US 5,866,590 lose exclusivity, and how do patent term and regulatory exclusivities interact?
Exclusivity timing framework (US)
For US patents, the practical end date is the later of:
- the patent’s expiration by term (typically 20 years from earliest effective US filing, subject to PTA adjustments), and
- any extended exclusivities that may exist due to regulatory exclusivity (not “patent term extension” unless eligible) and any Hatch-Waxman data exclusivity timing.
Important point for portfolio planning: for formulation patents like this, the relevant “entry clock” for generics often comes from:
- whether Orange Book-listed patents exist for the reference product and
- whether a Paragraph IV challenge is filed against those listed patents.
No Orange Book listing or reference product tie-in is provided in the prompt, so a precise “market exclusivity end” cannot be produced from the claim text alone.
What is the Orange Book status of tiagabine products tied to antioxidant-stabilized compositions?
Orange Book listing is a prerequisite for Paragraph IV
US 5,866,590 would matter to generic entry only if:
- it is listed in the Orange Book for a specific NDC of an approved reference product using tiagabine, and
- it is tied to the NDA/BLA in a way that enables a Paragraph IV certification.
No Orange Book NDC/NDA association is included in the provided information, so the listing status and any Paragraph IV history cannot be stated accurately.
What generic entry risks exist for competitors using tiagabine with different antioxidants or different granulation processes?
Risk vectors tied to the claim language
-
Using ascorbic acid but outside 5–25% loading
- If formulation uses ascorbic acid at stabilizing levels but outside the numeric range, claim 3 may fall away, but claim 1 may still remain a risk depending on “sufficient to stabilize” evidence.
-
Using only one of the vitamin E system components
- For claims 7–9, a competitor that uses alpha-tocopherol alone or ascorbyl palmitate alone may attempt to design around the “mixture of alpha-tocopherol and ascorbyl palmitate” requirement.
-
Process design-around
- If a competitor avoids melt granulation or does melt granulation under different controlled atmosphere conditions, they reduce exposure to process claims 5/6 and 11/12.
-
Physical form design-around
- Claim 2 and claim 8 require antioxidant “in the form of a powder.” Switching to non-powder forms could aim at that narrower feature.
Manufacturing/IP barrier reality
Even if a competitor changes formulation ingredients, they may still face risk if:
- the same antioxidant(s) are used, and
- melt granulation is performed with low moisture/oxygen controls consistent with the claims.
Conversely, teams that can switch process route away from melt granulation or use alternate stabilization systems can materially reduce the process-claim exposure.
How strong is the patent estate for 5,866,590: claim breadth, vulnerability points, and likely validity pressure
Claim breadth vs enforceability
- Moderate breadth on antioxidant system: Claim 1 is broad because it covers “ascorbic acid in an amount sufficient to stabilize.” That can be argued as wide, constrained only by functional “stabilize” language.
- Narrowing via numeric range in dependent claims: Claims 3 and 9 provide measurable constraints that can support clearer infringement or clearer non-infringement.
- Process claims are narrower in execution facts: melt granulation and low oxygen/low water vapor add evidentiary burden for both infringement and validity arguments.
Common validity pressure points for this claim style
While specific prior art references are not provided, patents framed around:
- antioxidant stabilization of drugs,
- using known antioxidants at certain ranges,
- and using controlled atmosphere processing,
typically face obviousness attacks if earlier art discloses similar stabilization systems.
From an enforcement standpoint, the functional language (“amount sufficient to stabilize”) can create both:
- factual disputes on stabilization effect, and
- argument space for design-around by using different stabilizers.
What patent litigation affects US 5,866,590 and what settlement signals exist?
No litigation docket numbers, parties, filings, or settlement documents are included in the prompt. A litigation impact analysis cannot be produced from the claim text alone.
How does US 5,866,590 compare with competing tiagabine stability patents (ascorbate vs tocopherol/ascorbyl palmitate and process controls)?
Delta analysis by antioxidant system
| Feature |
US 5,866,590 Ascorbic acid (Claims 1-3) |
US 5,866,590 Tocopherol+ascorbyl palmitate (Claims 7-9) |
| Antioxidant system |
Single antioxidant: ascorbic acid |
Two-component mixture required: alpha-tocopherol + ascorbyl palmitate |
| Key scope limiter |
“sufficient to stabilize” and optional numeric range |
“mixture” requirement and optional numeric range |
| Numeric range |
5–25 parts per 100 parts tiagabine HCl |
Same numeric range style: 5–25 parts per 100 parts tiagabine HCl |
| Design-around angle |
Substitute antioxidant system or change physical form |
Remove one component or change stabilizer system |
| Process overlay |
Melt granulation under low water vapor and low oxygen |
Same process overlay |
Delta analysis by process
Both systems share the same process limitations: melt granulation and controlled low moisture and low oxygen.
Business implication: if the commercial formulation uses melt granulation under controlled atmosphere, process-claim exposure increases even if antioxidant identity differs, unless the claims are tightly limited to ascorbic acid or tocopherol/ascorbyl palmitate.
Commercial and regulatory exposure: which competitors and dosage forms are most likely to trigger 5,866,590?
Dose form sensitivity
Antioxidant-stabilized tiagabine compositions most commonly matter in:
- solid oral dosage forms (tablets/capsules),
- where excipient and manufacturing conditions impact oxidative degradation.
Trigger conditions under 5,866,590:
- presence of tiagabine (or tiagabine HCl) in the composition
- presence of the specified antioxidant system
- and, for process claims, use of melt granulation under low water vapor and low oxygen.
Without NDC-level product specifics and Orange Book linkage, competitor identification is not supportable from the provided information.
Key Takeaways
- US 5,866,590 is built around tiagabine stabilization using specific antioxidants: ascorbic acid (claims 1–3) or alpha-tocopherol + ascorbyl palmitate (claims 7–9), plus a pharmaceutically acceptable carrier.
- The most enforceable product boundaries are the numeric loading ranges (claims 3 and 9): 5–25 parts by weight per 100 parts tiagabine hydrochloride.
- The strongest litigation hooks are the process claims requiring melt granulation (claims 5 and 11) under low water vapor pressure and low oxygen pressure (claims 6 and 12).
- Design-around opportunities exist by changing antioxidant chemistry, antioxidant physical form, avoiding melt granulation, or changing moisture/oxygen processing conditions.
- Orange Book status, Paragraph IV history, expiration-to-launch timing, and litigation/settlement impacts cannot be determined from the claim text alone.
FAQs
-
Does US 5,866,590 require the antioxidant to be present in powder form for all claims?
Only claims 2 and 8 add the “in the form of a powder” limitation; claims 1 and 7 do not.
-
If a competitor uses ascorbic acid but at 1% w/w vs 10%, which claims are most relevant?
Claim 3 likely does not apply due to the 5–25% range; claim 1 may still apply depending on whether the lower amount is argued to be “sufficient to stabilize.”
-
Can a competitor avoid claims 7–9 by using only alpha-tocopherol without ascorbyl palmitate?
Claims 7–9 require a “mixture of alpha-tocopherol and ascorbyl palmitate,” so removing one component targets the claim structure.
-
What is the most practically important limitation in the process claims?
Melt granulation and the controlled environment language (“low water vapor pressure and low oxygen pressure”), because they require documented manufacturing conditions.
-
Is the scope limited to tiagabine hydrochloride tablets?
The numeric ranges reference “tiagabine hydrochloride,” but the independent composition claims are written more broadly as “tiagabine or a pharmaceutically acceptable salt.”
References (APA)
- United States Patent 5,866,590.
More… ↓
⤷ Start Trial
|
